Eli Lilly and Company LLY

The bottom line

What moves this stock is the pace of growth in obesity and diabetes drugs: $22.97B quarterly revenue, up 47.7% year over year, with EPS of $8.38 versus a $6.01 estimate. A P/E of 43.9 against a peer median of 39.8 assumes that pace persists for a long time. Meanwhile Lilly is building a pipeline beyond obesity, as the ESMO ovarian cancer data shows, but that is still Phase 1 with Phase 3 only beginning. The central tension: the stock sits at 91% of its 52-week range at a fresh high, with $54.9B debt against $8.95B cash, and an October 29 report that has to meet those expectations.

An explanation of the mechanics from the facts on this page, not advice.

What the company does

Eli Lilly and Company is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $1.14T, based in the USA.

It employs about 50,000 people and has been listed since Jan 13, 1978.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 43.9 versus 39.8 for 4 direct peers — priced in line with its group.

Revenue is growing 48% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 24.8 — they expect higher earnings.

The average analyst price target is 1331.55, 5% above the current price (their view, not ours).

The stock sits at 91% of its one-year range (0% = the low, 100% = the high).

The risks

• • Net debt is 1.4× shareholders' equity — high leverage.
• • Quarterly report in 4 days (2026-10-29) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 31 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (26 vs 2).
• ✅ Revenue is growing 48% a year.
• ✅ Pays a dividend (0.5% a year).

What the market is talking about this week

A fresh stock high alongside encouraging early oncology data, days before the quarterly report.

• Eli Lilly presented Phase 1 data at ESMO for experimental cancer drug Sofe-M with Avastin: 79% confirmed response rate and 100% disease control in ovarian cancer. [2] [3]
• The drug is now in three Phase 3 trials (FRAmework-01) in platinum-resistant and platinum-sensitive ovarian cancer; common side effects included nosebleeds, nausea and anemia. [2] [3]
• The stock hit a 52-week high of $1,321.21, amid enthusiasm over its obesity and diabetes franchises. [5]
• In Q2 Lilly reported $22.97B revenue, up 47.7% — the fastest growth in the branded pharma group — and raised full-year guidance. [4]

A summary of the articles below only, each point with its source. Not a forecast, not a recommendation.

What to watch

• The quarterly report on October 29, 2026 — after a large beat last quarter, the market will check whether growth pace and full-year guidance hold. (2026-10-29)
• Progress of the Phase 3 FRAmework-01 program for Sofe-M in ovarian cancer — three study arms that will test whether the Phase 1 data hold up. [2] [3]
• Whether the stock holds above the $1,321.21 high set this week, versus an average analyst target around $1,331. [5]
• The free cash flow trend ($7.76B last quarter) against $54.9B of debt, in the upcoming report. (2026-10-29)

What changed this week

Over the past week the stock rose 1.3% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

It set a new one-year high this week.

This week's news

• Stock Market Action Plan: A Preelection Week Primer finance.yahoo.com · 2026-10-24
  General market preview of a heavy week of big-cap earnings, a Fed meeting and pre-election positioning; not specific to Lilly. source ↗
• Eli Lilly releases promising early-stage data on ADC for ovarian cancer seekingalpha.com · 2026-10-24
  Summary of Lilly's Phase 1 data for an ovarian cancer ADC: 79% response, 100% disease control, with side effects and the Phase 3 program detailed. source ↗
• Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 finance.yahoo.com · 2026-10-24
  Lilly's official release from ESMO in Madrid on Sofe-M plus bevacizumab data, including a quote from its oncology head on the need for new treatments. source ↗
• Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks finance.yahoo.com · 2026-10-24
  Comparison of Q2 results across branded pharma: Lilly grew fastest (47.7%), beat estimates by 11.4%, and the stock rose 17.3% since reporting. source ↗
• 3 Portfolio-Worthy Stocks Hitting 52-Week Highs: AAPL, LLY & KO finance.yahoo.com · 2026-10-23
  Article on three stocks hitting 52-week highs — Apple, Lilly and Coca-Cola; Lilly at $1,321.21 on obesity and diabetes drugs. source ↗
• Dow Jones Futures: Microsoft, Google, Amazon Lead Earnings Wave; What To Do In Mixed Market finance.yahoo.com · 2026-10-23
  Futures and market-open commentary about a wave of tech earnings; no Lilly-specific content. source ↗

What changed since last week

• The price rose 5.4% since the last summary.